Local reagent makes good

Genisphere turns old reagents into new nanoparticles, avoids liver

Genisphere LLC is converting its 19 year-old diagnostic reagents into new-age delivery vehicles. The company is repurposing its 3DNA assay technology into nanoparticles that it believes can bring high-valency cargo to target tissues without getting lost in the liver.

Today, Genisphere announced a collaborative research, option to license agreement with MedImmune LLC, the biologics unit of AstraZeneca plc - the biotech's first public deal with a major pharma.

The partners will develop nanoparticles with Genisphere's technology, using up to six of MedImmune's oncology molecules. Genisphere will receive an upfront payment, development milestones and future royalties upon MedImmune triggering an option, and developing and commercializing therapeutics from the partnership.

The company's 3DNA platform consists of DNA helices interlinked to form branched molecules that can be heavily laden with a wide variety of targeting agents and therapeutic cargos (see Figure: Arms wide open).

"Using a variety of chemistries, we can conjugate something as simple as a vitamin, or something as complicated as an antibody or whole gene, on the

Read the full 1667 word article

How to gain access

Continue reading with a
two-week free trial.